The German Cancer Research Center (DKFZ), the largest biomedical research institute in Germany operates a comprehensive program in the field of cancer research. Together with university partners at seven renowned partner sites, we have established the German Cancer Consortium (DKTK).
For the partner site of DKTK Freiburg the German Cancer Research Center is seeking a
Our long-term goal is a better understanding of the genetic and epigenetic pathomechanisms leading to leukemia and other cancers, and the development of innovative, chemotherapy-free therapies.
Our research activities include mechanistic studies of epigenetic gene silencing (resulting in tumor suppressor inactivation, arrested differentiation, and immune evasion), and the development of preclinical models to reactivate these silenced genes. Validation of these approaches includes correlative studies within clinical trials of DNA-hypomethylating drugs and other chromatin-modifying agents in acute myeloid leukemia (AML), in order to identify novel biomarkers for response to epigenetically active drugs (epi-drugs), and to better understand the genetic and epigenetic mechanisms of resistance to these therapies.
In order to more rapidly advance this "bench-to-bedside - and back" approach within a larger network of investigators, we are collaborating with numerous DKTK sites, e.g. via preclinical and correlative studies on LSD1 inhibition in AML within the LACID consortium of DKTK (which we coordinate together with M. Jung and R. Schüle). Similarly, we have initiated a DFG Priority Programme (SPP1463) on epigenetics of myeloid cancers (Coordinators: M. Lübbert, C. Plass) and participate in the DFG CRC992 (Medep). In order to advance epi-drug based therapies in the clinic, we are coordinating several national and European investigator-initiated clinical trials.
Experimental techniques used in the lab include culturing of AML and lung cancer cells, and purification of primary leukemia blood blasts from patients receving epi-drug therapies. Molecular biology techniques: DNA methylome analyses, RNA-Seq, ChIP-seq, pyro-sequencing, RT-qPCR etc. (treatment modeling in xenograft mouse models of leukemia within a collaboration).
We are seeking a highly motivated and independent postdoctoral fellow with a PhD / Dr. rer. nat. in biology (or related field) to conduct and supervise projects on epigenetic aberrations in different cancers and their targeting using epi-drugs. Experience in bioinformatic sequence analyses and in data integration is a prerequisite. The applicant should have a high level of self-motivation to develop scientific manuscripts and grants, and to present research results at national and international conferences. Strong organizational skills and teamwork abilities, also with regards to supervision of students and technicians, and of the curation of a bio-bank, are expected. She/he should have a genuine interest in epigenetics and translational research, enjoy the interaction with physician-scientists, and must have oral and written fluency of the English language.
If you are interested, please submit your CV, publication list, university degrees, contact details for at least three references online to the DKFZ.
The position is limited to 2 years. The position can in principle be part-time.
The Translation Center is located in the ZTZ (Center of Translational Cell Research) at the University Medical Center Freiburg.
For further information please contact
Prof. Dr. Michael Lübbert,
phone +49 761 270-35340.
The German Cancer Research Center is committed to increase the percentage of female scientists and encourages female applicants to apply. Among candidates of equal aptitude and qualifications, a person with disabilities will be given preference.
To apply for a position please use our online application portal (www.dkfz.de).
We ask for your understanding that we cannot return application documents that are sent to us by post (Deutsches Krebsforschungszentrum, Personalabteilung, Im Neuenheimer Feld 280, 69120 Heidelberg) and that we do not accept applications submitted via email. We apologize for any inconvenience this may cause.